Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Migraine Disorders: later-stage trial registry
5 of 22 indexed Migraine Disorders trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #756 of 28,707 conditions by registered trial count.
22 US clinical trials · 5 currently recruiting · #756 of 28,707 conditions by registered trial count
Migraine Disorders: 22 US clinical trials tracked, 5 recruiting.
Migraine Disorders is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 6 of these trials.
Enrollment posture brief
Registry condition migraine-disorders
OPEN 5 | RECR 23% | LATE 9 | EARLY 4 | RANK #756 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Hypogonadism (23% recruiting · 22 trials)
Migraine Disorders lists 5 open slots (23% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Migraine Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Migraine Disorders is recruiting below its size-band peers.
5 of 22 indexed trials (22.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Migraine Disorders research.
GlaxoSmithKline accounts for 6 of 22 trials (27.3%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Migraine Disorders enrolment sits around 260 participants.
Median target enrolment is 260 among the 22 trials that report a genuine target (sentinel values excluded). 7 of those (31.8%) plan for fewer than 100 participants.
-
Migraine Disorders research is mostly interventional.
20 interventional and 2 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
22 total, page 1 of 1
Responding With Evidence and Access for Childhood Headaches
Children's Hospital Medical Center, Cincinnati
NCT05889624
Mind Body Balance for Pediatric Migraine
Children's Hospital Medical Center, Cincinnati
NCT04715685
Migraine Manager (R01)
Children's Hospital Medical Center, Cincinnati
NCT04567355
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
Upsher-Smith Laboratories
NCT04748601
Determining the Utility of a Behavioral Intervention in Chronic Migraine
Mayo Clinic
NCT05415020
Intervention for Sleep and Pain in Youth: a Randomized Controlled Trial
Seattle Children's Hospital
NCT04936321
An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention
Ki Health Partners.
NCT06154070
Phase 3 Study of MAP0004 in Adult Migraineurs
Allergan
NCT00623636
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
Alder Biopharmaceuticals
NCT02559895
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
GlaxoSmithKline
NCT00488514
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
GlaxoSmithKline
NCT00240617
Prevention Study in Adult Patients Suffering From Migraine Headaches
XenoPort
NCT00742209
A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
GlaxoSmithKline
NCT00792636
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
GlaxoSmithKline
NCT00573170
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea
GlaxoSmithKline
NCT00329459
Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults
Allergan
NCT02191579
Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines
ElectroCore
NCT03716505
Integrative Migraine Pain Alleviation Through Chiropractic Therapy
Harvard University Faculty of Medicine
NCT03177616
A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.
GlaxoSmithKline
NCT00989625
A Study of Home-Delivered Neurostimulation for Migraine
MJHS Institute for Innovation in Palliative Care
NCT03874351
Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)
Sorrento Therapeutics
NCT03229798
Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
Quality Living
NCT03662295
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 6 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Migraine Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Migraine Disorders trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Migraine Disorders page
22 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Migraine Disorders trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- GlaxoSmithKline sponsors the most Migraine Disorders trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Migraine Disorders condition card totals 22 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.